Ergomed plc Board changes (4305Z)
15 December 2017 - 6:00PM
UK Regulatory
TIDMERGO
RNS Number : 4305Z
Ergomed plc
15 December 2017
PRESS RELEASE
Board changes
Stephen Stamp appointed as CEO and Jan Petracek as COO
London, UK - 15 December 2017: Ergomed plc (LSE: ERGO)
('Ergomed' or the 'Company'), a specialised pharmaceutical services
and drug development company, today announces changes to its Board
and management team with the appointment of Stephen Stamp as Chief
Executive Officer and Dr Jan Petracek as Chief Operating Officer
and a Board Director of Ergomed with immediate effect. Dr Dan Weng
has decided to step down as CEO with immediate effect.
Stephen Stamp has been Ergomed's Chief Financial Officer, and
member of the Board of Directors, since January 2016. Prior to
this, he had spent more than 30 years in corporate finance and
general management in both public and private companies in the UK
and the USA. He has held senior roles at a number of healthcare
businesses in the UK and US and, as CFO, led the IPO of Shire on
the London Stock Exchange and NASDAQ as well as a number of major
acquisitions. A search for a new CFO will be undertaken.
Dr Jan Petracek has been CEO of Ergomed's pharmacovigilance
subsidiary PrimeVigilance, since April 2017, having joined the
Company in November 2016 following the acquisition of European
PharmInvent Services s.r.o. where he was CEO. Dr Petracek is the
former Head of Risk Management Section at the European Medicines
Agency, and the former Head of Pharmacovigilance, Strategy and
Development at the State Institute for Drug Control in the Czech
Republic.
Peter George, Chairman of Ergomed, said: "Stephen has
exceptionally wide business experience and has developed a deep
understanding of Ergomed and its markets. His move to CEO makes
strong strategic sense as the Company looks to continue to deliver
on its strategy. I am also delighted to have Jan join the Board as
COO. He has added significant value to the executive management
team since joining Ergomed in 2016 and his vision and drive has
contributed substantially to our pharmacovigilance business which
continues to significantly outpace the growth of a fast growing
market. We look forward to his contribution across our wider
services business and the Company as a whole.
"I'd like to thank Dan for his contributions this year and wish
him well with his future endeavours."
Dr Jan Petracek, aged 42, currently holds the following
directorships and has held no other directorships in the past five
years:
Current directorships: European Pharminvent Services s.r.o.
Pharminvent regulatory s.r.o.
PrimeVigilance d.o.o. Beograd-Novi
Beograd
PrimeVigilance Inc.
PRIMEVIGILANCE LIMITED
PrimeVigilance Zagreb d.o.o.
SOUND OPINION LIMITED
Dr Jan Petracek holds 367,597 Ordinary Shares of 1 penny each in
the Company.
Ergomed confirms that there are no further disclosures to be
made in relation to Rule 17 of paragraph (g) of Schedule Two of the
AIM Rules for Companies in respect of Dr Petracek's
appointment.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0)
1483 503205
Peter George (Chairman)
Stephen Stamp (Chief Executive
Officer)
Numis Securities Limited Tel: +44 (0)
20 7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0)
20 7496 3000
Alex Price (Joint Broker)
Consilium Strategic Communications Tel: +44 (0)
- for UK enquiries 20 3709 5700
Chris Gardner / Mary-Jane ergomed@consilium-comms.com
Elliott
Ivar Milligan / Philippa Gardner
MC Services - for Continental Tel: +49 211
European enquiries 5292 5222
Anne Hennecke
About Ergomed
Ergomed provides specialist services to the pharmaceutical
industry and develops drugs both wholly-owned and through
partnerships. Ergomed's fast-growing, profitable service offering
spans all phases of clinical development and post-approval
pharmacovigilance and medical information. Drawing on more than 20
years of expertise in drug development, Ergomed is also building a
growing portfolio of drug development partnerships and programmes,
including wholly-owned proprietary products for the treatment of
surgical bleeding. For further information, visit:
http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFVDFDLSLID
(END) Dow Jones Newswires
December 15, 2017 02:00 ET (07:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024